NEW YORK, May 28, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, will be added to the Morgan Stanley Capital International (MSCI) Global Micro Cap Index, effective May 30, 2014. Tonix develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia (FM), post-traumatic stress disorder (PTSD) and episodic tension-type headache.
"It is gratifying that Tonix's progress in the last year has been recognized by MSCI through inclusion in its index, as well as by the investment community at large," said Seth Lederman, M.D., president and chief executive officer of Tonix. "Recently, we announced the completion of enrollment in our BESTFIT trial for FM which, if positive, will serve as the first of two pivotal trials required for FDA approval. We continue to anticipate initiating a Phase 2 trial for PTSD in the third quarter and a clinical pharmacology study for episodic tension-type headache in the fourth quarter."
MSCI Inc. is a leading provider of investment decision support tools to investors worldwide, including asset managers, banks, hedge funds and pension funds. Among MSCI's products are its worldwide indices used in assessing portfolio risks and performance. Companies are moved in and out of these indices twice a year based on certain size and liquidity requirements.
About Tonix Pharmaceuticals Holding Corp.
Tonix develops first-in-class medicines for common disorders of the central nervous system. Fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache are characterized by inadequate treatment options, dissatisfaction expressed among patients and physicians, and significant economic impact. Tonix is currently conducting the first anticipated pivotal trial of TNX-102 SL in FM, the BESTFIT trial (BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy). Tonix expects to begin clinical development of TNX-102 SL in PTSD in the third quarter of 2014. With TNX-102 SL, Tonix approaches the treatment of people suffering from FM and PTSD by targeting their inability to obtain restorative sleep. TNX-201 is in development for episodic tension-type headache, and Tonix expects to begin clinical studies of TNX-201 in the fourth quarter of 2014. To learn more, please visit www.tonixpharma.com.
About MSCI Inc.
MSCI Inc. is a leading provider of investment decision support tools to investors globally, including asset managers, banks, hedge funds and pension funds. MSCI products and services include indexes, portfolio risk and performance analytics, and governance tools.
The company's flagship product offerings are: the MSCI indexes with close to USD 7 trillion estimated to be benchmarked to them on a worldwide basis; Barra multi-asset class factor models, portfolio risk and performance analytics; RiskMetrics multi-asset class market and credit risk analytics; IPD real estate information, indexes and analytics; MSCI ESG (environmental, social and governance) research screening, analysis and ratings; ISS governance research and outsourced proxy voting and reporting services; and FEA valuation models and risk management software for the energy and commodities markets. MSCI is headquartered in New York, with research and commercial offices around the world.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 28, 2014 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
CONTACT: Tonix Pharmaceuticals Holding Corp. Leland Gershell Chief Financial Officer (212) 980-9155 x104 email@example.com Public Relations: Dian Griesel Int'l. Susan Forman (212) 825-3210 firstname.lastname@example.org Media Relations: JQA Partners, LLC Jules Abraham (917) 885-7378 email@example.comSource: Tonix Pharmaceuticals Holding, Inc.